CAJ | 학술논문

目的探讨腹腔镜袖状胃切除术(LSG)治疗肥胖症及肥胖相关疾病的安全性和有效性.方法回顾性分析2006年12月至2011年7月间在浙江省人民医院接受LSG术的67例肥胖症患者的临床资料.观察术后1年患者体质量指数(BMI)、多余体质量减少率(EWL)以及2型糖尿病、高血压等肥胖相关疾病的改善情况.结果 67例患者均顺利完成LSG术,手术时间(78±17)min,术后住院时间(5.0±1.7)d.术后恢复均顺利,无围手术期死亡及术后严重并发症发生.64例(95.5％)患者获得术后1年的随访,BMI由术前的(37.7±4.1)kg/m2下降了(10.4±3.7)kg/m2,EWL为(80.2±27.7)％.2型糖尿病和高血压的治愈率分别为53.8％(7/13)和45.5％(5/11),缓解率均达100％.高三酰甘油血症(51例)、高尿酸血症(42例)、睡眠呼吸暂停综合征(2例)、骨关节疾病(9例)和棘皮病(8例)等其他肥胖相关疾病也得到治愈或不同程度的改善.结论 LSG治疗肥胖症是安全可行的,在明显减轻体质量的同时还能治愈或改善2型糖尿病和高血压等肥胖相关疾病.
목적 탐토복강경수상위절제술(LSG)치료비반증급비반상관질병적안전성화유효성.방법 회고성분석2006년12월지2011년7월간재절강성인민의원접수LSG술적67례비반증환자적림상자료.관찰술후1년환자체질량지수(BMI)、다여체질량감소솔(EWL)이급2형당뇨병、고혈압등비반상관질병적개선정황.결과 67례환자균순리완성LSG술,수술시간(78±17)min,술후주원시간(5.0±1.7)d.술후회복균순리,무위수술기사망급술후엄중병발증발생.64례(95.5％)환자획득술후1년적수방,BMI유술전적(37.7±4.1)kg/m2하강료(10.4±3.7)kg/m2,EWL위(80.2±27.7)％.2형당뇨병화고혈압적치유솔분별위53.8％(7/13)화45.5％(5/11),완해솔균체100％.고삼선감유혈증(51례)、고뇨산혈증(42례)、수면호흡잠정종합정(2례)、골관절질병(9례)화극피병(8례)등기타비반상관질병야득도치유혹불동정도적개선.결론 LSG치료비반증시안전가행적,재명현감경체질량적동시환능치유혹개선2형당뇨병화고혈압등비반상관질병.
Objective To investigate the safety and efficacy of laparoscopic sleeve gastrectomy(LSG)for the treatment of obesity and related diseases.Methods Clinical data of 67 patients who underwent LSG between December 2006 and July 2011 were analyzed retrospectively.Improvements in body mass index(BMI),percentage of excess weight loss(EWL),type 2 diabetes mellitus,hypertension and other comorbidities were observed at one year postoperatively.Results Laparoscopic procedures were completed in 67 patients without conversion.The operative time was(78±17)min.The postoperative hospital stay was(5.0±l.7)d.The postoperative recovery was uneventful and there were no perioperative death or severe postoperative complication.Sixty-four patients(95.5％)had a postoperative follow up of 1 year.One year after LSG,BMI decreased by(10.4±3.7)kg/m2 from(37.7±4.1)kg/m2 preoperatively and EWL was(80.2±27.7)％.In 13 cases of type 2 diabetes mellitus,7 patients(53.8％,7/13)were weaned off hypoglycemic agents or insulin.In 11 cases of hypertension,5 required no medications(45.5％,5/11).The remission rate was both 100％.There was significant resolution or improvement of other obesity-related comorbidiities,including hyper-triglyceridemia(n=51),hyperuricemia(n=42),sleep apnea syndrome(n=2),osteoarticular disease(n=9),and acanthosis(n=8).Conclusions LSG is safe and feasible for the treatment of obesity and can cure or improve type 2 diabetes mellitus,hypertension and other obesity related comorbidities.